- PR Newswire•21 hours agoEvogen and UCB Announce Collaboration for Further Development of EvoScore™ START for Improved Diagnosis of Epilepsy
PHILADELPHIA and ATLANTA, Dec. 5, 2016 /PRNewswire/ -- Evogen, Inc., a leader in proteomics and genomics-based testing for improved diagnosis and treatment of neurological disorders, and UCB, a global biopharmaceutical company with more than 20 years of experience in the research and development of anti-epileptic drugs, today announced a collaboration for further development of EvoScore™ START, Evogen's new proteomics-based blood test designed to accurately distinguish epileptic seizures from other events. The accurate diagnosis of epilepsy seizures remains a challenge to physicians and patients.
- PR Newswire•4 days ago
BRUSSELS, Dec. 2, 2016 /PRNewswire/ -- UCB is pleased to announce that 12 scientific abstracts have been accepted for poster presentation at the upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ...
- PR Newswire•21 days agoThe Lancet Publishes First Head-to-Head Study of CIMZIA® (certolizumab pegol) and Humira® (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients
The study compared CIMZIA® (certolizumab pegol) plus methotrexate (MTX) to Humira® (adalimumab) plus MTX in adult patients with moderate to severe rheumatoid arthritis (RA) who were inadequate responders to MTX. The study did not meet its primary endpoints for superiority, demonstrating no statistically significant difference in efficacy between CIMZIA® and Humira® in combination with MTX in both short-term (12-week) and long-term (2-year) evaluations.
UCBJY : Summary for UCB UNSP ADR EACH REPR 0.5 ORD - Yahoo Finance
UCB S.A. (UCBJY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||17.20|
|Dividend & Yield||0.63 (1.99%)|
|1y Target Est||N/A|